GHRH Analog

CJC-1295 DAC

Not FDA approvedRecovery & tissue repairWeight & metabolicBrain, mood & sleepLongevity & cellularGH axis & hormones
4.4/10

BioHarmony verdict

Caution

CJC-1295 with DAC is the long-acting form, dosed about weekly, that keeps growth hormone elevated for 6 to 8 days. It has the most human pharmacology data of any CJC-1295 form, per Teichman 2006, but no human outcome trial, and its development was halted after a trial death never linked to the drug.

Read full report

What is CJC-1295 DAC?

CJC-1295 with DAC is the long-acting version of a lab-made peptide that tells your pituitary to release growth hormone, and the "DAC" is what makes it both distinctive and divisive. The Drug Affinity Complex binds the peptide to albumin in your blood, stretching its life to 6 to 8 days. Instead of the short, natural pulse the no-DAC form produces, it keeps growth hormone elevated continuously, a sustained "bleed." That buys once-weekly convenience, which is its main selling point.

From the BioHarmony report, reviewed 2026-09-19.

Safety watch-outs

  • Chest pain, severe headache, or a high blood-pressure reading: stop and seek care
  • the cardiovascular risk cannot be reversed quickly with this form.
  • Worsening reaction with each weekly dose (possible immune sensitization): stop immediately.
  • Rising fasting glucose or HbA1c: stop and consult a clinician, especially with diabetes.
  • Any active or suspected cancer: do not use

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for CJC-1295 DAC yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (1)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalNot FDA approved
CompoundingWithdrawn from Category 2 nomination; eligibility is not established
Last checked2026-07-13
Next review2026-10-11

FDA identifies immunogenicity and peptide-impurity concerns for compounded CJC-1295 and reports limited clinical data plus serious adverse events.

Primary sources

  1. 7.5/10BPC-157Strong recommendRecoveryNot FDA approvedBPC-157 is a 15-amino-acid gastric peptide fragment with consistent preclinical repair data, including a 2025 sports-medicine systematic review of 36 studies with 35…
  2. 7.5/10TB-500 (Thymosin Beta-4 Fragment)Strong recommendRecoveryNot FDA approvedTB-500 is a synthetic LKKTETQ fragment marketed for soft-tissue repair, but most human evidence is on full-length topical thymosin beta-4: Sosne 2023 reported corneal…
  3. 7.4/10GHK-Cu (Copper Peptide)Strong recommendRecoveryNot FDA approvedGHK-Cu is a human copper-binding tripeptide with the best evidence for topical skin repair and wound healing, including Mulder 1994 diabetic ulcer data showing 98.5%…
  4. 7.3/10Thymosin Alpha-1Strong recommendRecoveryNot FDA approvedFDA identifies immunogenicity and peptide-impurity concerns for compounded thymosin alpha-1 and says available safety information is inadequate.

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.